AlphaStocks
6.4
Consider Buy

LEMAITRE VASCULAR INC (LMAT)

Health Care / Health Care Equipment

S&P SmallCap 600

$108.96

Middle of the pack. No strong signal either way.

Consider Buy

Score based on 5 of 5 models — high confidence

#201out of 1127 in Health Care

Is LEMAITRE VASCULAR INC a Good Investment in 2026?

LEMAITRE VASCULAR INC (LMAT) scores 6.4 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Piotroski model rates LEMAITRE VASCULAR INC as Attractive (6/9). However, the Greenblatt Magic Formula model rates it Caution — Bottom half (rank 62%). LEMAITRE VASCULAR INC currently trades above its estimated fair value of $67, suggesting limited upside at current prices. LEMAITRE VASCULAR INC ranks #201 out of 1127 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E43.3ROE14.9Market Cap2BDiv Yield0.7

Estimated Fair Value

$67.4262% above

Trading above estimated fair value. P/e of 43x implies high growth expectations.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Attractive

6/9

Buffett

Attractive

Business quality & competitive moat

Graham

Neutral

Significantly above fair value

Lynch

Neutral

PEG 1.9 · Fast Grower

Greenblatt

Caution

Bottom half (rank 62%)

Frequently Asked Questions

Is LEMAITRE VASCULAR INC (LMAT) a good investment?
Based on AlphaStocks' composite analysis, LEMAITRE VASCULAR INC (LMAT) scores 6.4 out of 10, earning a Consider Buy rating. This is a middle-of-the-pack score with no strong signal either way. Trading above estimated fair value. P/e of 43x implies high growth expectations.
What is LEMAITRE VASCULAR INC's Piotroski F-Score?
LEMAITRE VASCULAR INC's Piotroski F-Score status is Attractive. The raw score is 6/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is LMAT overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $67, LMAT appears overvalued. The stock currently trades 62% above its estimated fair value. Trading above estimated fair value. P/e of 43x implies high growth expectations.
How does LMAT compare to other Health Care stocks?
LEMAITRE VASCULAR INC ranks #201 out of 1127 stocks in the Health Care sector, placing it in the top 18% of its sector by composite score. This is a strong position relative to sector peers.
What do investment models say about LMAT?
AlphaStocks evaluates LMAT using five proven investment models. Piotroski: Attractive; Buffett: Attractive; Graham: Neutral; Lynch: Neutral; Greenblatt Magic Formula: Caution. These models are combined into a single composite score of 6.4/10.

Similar Stocks

PARRFTIAZN

Compare LMAT with

LMAT vs PARRLMAT vs FTILMAT vs AZN

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer